Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 14: 1126392, 2023.
Article in English | MEDLINE | ID: mdl-37033973

ABSTRACT

Because of the rapid mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an effective vaccine against SARS-CoV-2 variants is needed to prevent coronavirus disease 2019 (COVID-19). T cells, in addition to neutralizing antibodies, are an important component of naturally acquired protective immunity, and a number of studies have shown that T cells induced by natural infection or vaccination contribute significantly to protection against several viral infections including SARS-CoV-2. However, it has never been tested whether a T cell-inducing vaccine can provide significant protection against SARS-CoV-2 infection in the absence of preexisting antibodies. In this study, we designed and evaluated lipid nanoparticle (LNP) formulated mRNA vaccines that induce only T cell responses or both T cell and neutralizing antibody responses by using two mRNAs. One mRNA encodes SARS-CoV-2 Omicron Spike protein in prefusion conformation for induction of neutralizing antibodies. The other mRNA encodes over one hundred T cell epitopes (multi-T cell epitope or MTE) derived from non-Spike but conserved regions of the SARS-CoV-2. We show immunization with MTE mRNA alone protected mice from lethal challenge with the SARS-CoV-2 Delta variant or a mouse-adapted virus MA30. Immunization with both mRNAs induced the best protection with the lowest viral titer in the lung. These results demonstrate that induction of T cell responses, in the absence of preexisting antibodies, is sufficient to confer protection against severe disease, and that a vaccine containing mRNAs encoding both the Spike and MTE could be further developed as a universal SARS-CoV-2 vaccine.


Subject(s)
COVID-19 Vaccines , COVID-19 , Animals , Humans , Mice , COVID-19/prevention & control , SARS-CoV-2 , Antibodies, Neutralizing , Epitopes, T-Lymphocyte , RNA, Messenger/genetics
2.
J Biomed Mater Res B Appl Biomater ; 101(2): 330-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23115065

ABSTRACT

Microsphere-based polymeric tissue-engineered scaffolds offer the advantage of shape-specific constructs with excellent spatiotemporal control and interconnected porous structures. The use of these highly versatile scaffolds requires a method to sinter the discrete microspheres together into a cohesive network, typically with the use of heat or organic solvents. We previously introduced subcritical CO(2) as a sintering method for microsphere-based scaffolds; here we further explored the effect of processing parameters. Gaseous or subcritical CO(2) was used for making the scaffolds, and various pressures, ratios of lactic acid to glycolic acid in poly(lactic acid-co-glycolic acid), and amounts of NaCl particles were explored. By changing these parameters, scaffolds with different mechanical properties and morphologies were prepared. The preferred range of applied subcritical CO(2) was 15-25 bar. Scaffolds prepared at 25 bar with lower lactic acid ratios and without NaCl particles had a higher stiffness, while the constructs made at 15 bar, lower glycolic acid content, and with salt granules had lower elastic moduli. Human umbilical cord mesenchymal stromal cells (hUCMSCs) seeded on the scaffolds demonstrated that cells penetrate the scaffolds and remain viable. Overall, the study demonstrated the dependence of the optimal CO(2) sintering parameters on the polymer and conditions, and identified desirable CO(2) processing parameters to employ in the sintering of microsphere-based scaffolds as a more benign alternative to heat-sintering or solvent-based sintering methods.


Subject(s)
Tissue Scaffolds , Biomechanical Phenomena , Carbon Dioxide , Cell Survival , Cells, Cultured , Humans , Lactic Acid , Materials Testing , Mesenchymal Stem Cells/cytology , Microscopy, Electron, Scanning , Microspheres , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Porosity , Tissue Engineering/instrumentation , Tissue Engineering/methods , Umbilical Cord/cytology
4.
J Periodontol ; 79(8): 1457-64, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18672996

ABSTRACT

BACKGROUND: The cholesterol-lowering drug simvastatin promotes bone formation in cell cultures and animal models. In previous studies, devices for the controlled, localized delivery of simvastatin hydroxyacid enhanced osteoblastic activity in vitro. The objective of this investigation was to determine bioactivity of the delivery system in vivo. METHODS: Devices for sustained or intermittent release of simvastatin hydroxyacid were formed using a blend of cellulose acetate phthalate and a poly(ethylene oxide) and poly(propylene oxide) block copolymer, and they were implanted directly over the calvarium of young male rats. Drug-free devices were used as controls. After 9, 18, or 28 days, specimens were histologically evaluated for new bone formation. RESULTS: All three groups showed some level of new bone formation, but the extent of osteogenesis depended on the type of implant. Devices delivering simvastatin hydroxyacid were associated with a 77.5% to 133% increase in new woven bone thickness compared to control devices without a drug (P<0.05). Furthermore, intermittent release stimulated a 32.3% greater response in bone thickness and a 74.1% greater bone area than did sustained delivery (P<0.05). Although a minimal thickness of woven bone was formed directly under the device (up to 36 microm), a significantly thicker layer was observed at the periphery (up to 205 microm), implying mechanical and/or chemical effects directly under the implant. The percentage of lamellar bone area for intermittent and sustained release was higher than that for the control group (P<0.05). CONCLUSION: Based on the present results of enhanced bone formation, these devices for the intermittent delivery of simvastatin hydroxyacid merit further attention for localized osteogenesis.


Subject(s)
Drug Delivery Systems , Hydroxymethylglutaryl CoA Reductases/administration & dosage , Osteogenesis/drug effects , Simvastatin/analogs & derivatives , Simvastatin/administration & dosage , Administration, Topical , Animals , Cellulose/analogs & derivatives , Delayed-Action Preparations , Drug Carriers , Lactic Acid , Male , Microspheres , Models, Animal , Polyethylene Glycols , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Rats , Rats, Sprague-Dawley , Skull/drug effects , Skull/pathology , Time Factors
5.
Biomaterials ; 29(26): 3591-8, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18514812

ABSTRACT

Regeneration of bone is driven by the action of numerous biomolecules. However, most osteobiologic devices mainly depend on delivery of a single molecule. The present studies were directed at investigating a polymeric system that enables localized, alternating delivery of two or more biomolecules. The osteotropic biomolecules studied were simvastatin hydroxyacid (Sim) and parathyroid hormone (1-34) (PTH(1-34)), and the antimicrobial peptide cecropin B (CB) was also incorporated. Loaded microspheres were made using the complexation polymer system of cellulose acetate phthalate and Pluronic F-127 (blend ratio, 7:3). By alternating layers of the different types of microspheres, 10-layer devices were made to release CB and Sim, CB and PTH, or Sim and PTH. In vitro experiments showed five discrete peaks for each molecule over a release period of approximately two weeks. MC3T3-E1 osteoblastic cells alternately exposed to the osteotropic biomolecules showed enhanced proliferation and early osteoblastic activity. Alternating delivery of 10nm Sim and either 500pg/ml or 5ng/ml PTH showed additive effects compared to the CB/Sim or CB/PTH devices. These implantable formulations may be useful for alternating delivery of different biomolecules to stimulate concurrent biological effects in focal tissue regeneration applications.


Subject(s)
Bone Regeneration/physiology , Drug Carriers/chemistry , Drug Delivery Systems , Polymers/chemistry , 3T3 Cells , Animals , Anticholesteremic Agents/chemistry , Biocompatible Materials/chemistry , Biocompatible Materials/metabolism , Hydrogen-Ion Concentration , Insect Proteins/chemistry , Insect Proteins/metabolism , Materials Testing , Mice , Microspheres , Simvastatin/analogs & derivatives , Simvastatin/chemistry , Simvastatin/metabolism
6.
Int J Pharm ; 340(1-2): 6-12, 2007 Aug 01.
Article in English | MEDLINE | ID: mdl-17433584

ABSTRACT

The association polymer system of cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) was used to create intermittent release devices for mimicking the daily injection of simvastatin that has been reported to stimulate bone formation. To enhance solubility in water, prodrug simvastatin was modified by lactone ring opening, which converts the molecule to its hydroxyacid form. CAP/PF-127 microspheres incorporating simvastatin acid were prepared by a water-acetone-oil-water (W/A/O/W) triple emulsion process. Devices were then fabricated by pressure-sintering UV-treated blank and drug-loaded microspheres. Using a multilayered fabrication approach, pulsatile release profiles were obtained. Delivery was varied by changing loading, number of layers, blend ratio, and incubation conditions. To determine the cellular effects of intermittent exposure to simvastatin acid, MC3T3-E1 cells were cultured with either alternating or sustained concentrations of simvastatin acid in the medium, and DNA content, alkaline phosphatase activity, and osteocalcin secretion were measured. For all three cell responses, cultures exposed to simvastatin acid showed higher activity than did control cultures. Furthermore, cell activity was greater for cells cultured with intermittent concentrations of simvastatin acid compared to cells that were constantly treated. These results imply that devices intermittently releasing simvastatin acid warrant further study for locally promoting osteogenesis.


Subject(s)
Bone Density Conservation Agents/chemistry , Cellulose/analogs & derivatives , Drug Carriers , Poloxamer/chemistry , Simvastatin/analogs & derivatives , 3T3 Cells , Acetone/chemistry , Alkaline Phosphatase/metabolism , Animals , Bone Density Conservation Agents/pharmacology , Cell Proliferation , Cell Survival , Cellulose/chemistry , Cellulose/toxicity , Chemistry, Pharmaceutical , DNA Replication , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Compounding , Emulsions , Kinetics , Mice , Microspheres , Oils/chemistry , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteocalcin/metabolism , Poloxamer/toxicity , Simvastatin/chemistry , Simvastatin/pharmacology , Solubility , Technology, Pharmaceutical , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...